Literature DB >> 10092629

RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity.

C M Niswender1, S C Copeland, K Herrick-Davis, R B Emeson, E Sanders-Bush.   

Abstract

RNA transcripts encoding the serotonin 5-hydroxytryptamine 2C (5-HT2C) receptor (5-HT2CR) undergo adenosine-to-inosine RNA editing events at up to five specific sites. Compared with rat brain, human brain samples expressed higher levels of RNA transcripts encoding the amino acids valine-serine-valine (5-HT2C-VSV) and valine-glycine-valine (5-HT2C-VGV) at positions 156, 158, and 160, respectively. Agonist stimulation of the nonedited human receptor (5-HT2C-INI) and the edited 5-HT2C-VSV and 5-HT2C-VGV receptor variants stably expressed in NIH-3T3 fibroblasts demonstrated that serotonergic agonists were less potent at the edited receptors. Competition binding experiments revealed a guanine nucleotide-sensitive serotonin high affinity state only for the 5-HT2C-INI receptor; the loss of high affinity agonist binding to the edited receptor demonstrates that RNA editing generates unique 5-HT2CRs that couple less efficiently to G proteins. This reduced G protein coupling for the edited isoforms is primarily due to silencing of the constitutive activity of the nonedited 5-HT2CR. The distinctions in agonist potency and constitutive activity suggest that different edited 5-HT2CRs exhibit distinct responses to serotonergic ligands and further imply that RNA editing represents a novel mechanism for controlling physiological signaling at serotonergic synapses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092629     DOI: 10.1074/jbc.274.14.9472

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  113 in total

Review 1.  Imprinted expression of small nucleolar RNAs in brain: time for RNomics.

Authors:  W Filipowicz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

Review 2.  Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery.

Authors:  R A de Ligt; A P Kourounakis; A P IJzerman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 3.  Small nucleolar RNAs: versatile trans-acting molecules of ancient evolutionary origin.

Authors:  Michael P Terns; Rebecca M Terns
Journal:  Gene Expr       Date:  2002

Review 4.  RNA editing by adenosine deaminases that act on RNA.

Authors:  Brenda L Bass
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

5.  A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains.

Authors:  C X Chen; D S Cho; Q Wang; F Lai; K C Carter; K Nishikura
Journal:  RNA       Date:  2000-05       Impact factor: 4.942

6.  Host response to polyomavirus infection is modulated by RNA adenosine deaminase ADAR1 but not by ADAR2.

Authors:  Cyril X George; Charles E Samuel
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

7.  Serotonin 2c receptor RNA editing in major depression and suicide.

Authors:  Rebecca Lyddon; Andrew J Dwork; Mehdi Keddache; Larry J Siever; Stella Dracheva
Journal:  World J Biol Psychiatry       Date:  2012-03-09       Impact factor: 4.132

8.  Key issues in the computational simulation of GPCR function: representation of loop domains.

Authors:  E L Mehler; X Periole; S A Hassan; H Weinstein
Journal:  J Comput Aided Mol Des       Date:  2002-11       Impact factor: 3.686

9.  RNA editing generates tissue-specific sodium channels with distinct gating properties.

Authors:  Weizhong Song; Zhiqi Liu; Jianguo Tan; Yoshiko Nomura; Ke Dong
Journal:  J Biol Chem       Date:  2004-05-10       Impact factor: 5.157

10.  Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene.

Authors:  Rachel Flomen; Joanne Knight; Pak Sham; Robert Kerwin; Andrew Makoff
Journal:  Nucleic Acids Res       Date:  2004-04-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.